Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
Article
in English
| IMSEAR
| ID: sea-41240
ABSTRACT
OBJECTIVE:
To conduct a cost-utility analysis on recombinant human erythropoietin (rHuEPO) for treating anemic cancer patients induced by chemotherapy compared to blood transfusion alone under the Thai health care setting. MATERIALS ANDMETHODS:
A health care provider's perspective was used to examine relevant costs and outcomes using the Markov model. Cost data were estimated based on the reference price set by the Ministry of Public Health. The effectiveness data were obtained from a systematic review of published literature. The results were presented in terms of incremental cost-effectiveness ratio (ICER) in Thai Baht per Quality Adjusted Life Years (QALYs) gained. A probabilistic sensitivity analysis method was performed.RESULTS:
The ICERs of rHuEPO compared to blood transfusion alone were 3.7 and 2.7 millions Baht per QALY for patients with hemoglobin less than 8 g/dl and 8-9 g/dl, respectively. The rHuEPO required additional resources (more costly) with less benefit compared to blood transfusion for patients with hemoglobin 9-10 g/dl.CONCLUSIONS:
The rHuEPO may be cost-ineffective for the treatment of anemia caused by chemotherapy in cancer patients in Thailand.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Thailand
/
Blood Transfusion
/
Humans
/
Probability
/
Markov Chains
/
Erythropoietin
/
Cost-Benefit Analysis
/
Quality-Adjusted Life Years
/
Anemia
/
Neoplasms
Type of study:
Health economic evaluation
Country/Region as subject:
Asia
Language:
English
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS